Fig 1: MMPs and CDKs are the targets of WDR5. (A) Results of ChIP-seq and bioinformatics analysis on L02 with or without CCDC144NL-AS1 overexpression showed the involvement of cancer metastasis (MMP2 and MMP9) and the cell cycle (CDK1, CDK2, and CDK4) pathways in CCDC144NL-AS1-overexpressed cells. (B) Results of Western blotting showed that the expression of MMPs and CDKs are regulated by CCDC144NL-AS1/miR-940/WDR axis.
Fig 2: Expression pattern of CCDC144NL-AS1/miR-940/WDR5, MMPs, and CDKs in mice HCC model. (A) RT-qPCR showed that the expression of CCDC144NL-AS1 increased markedly in mouse HCC tissue compared to that in the normal liver tissue, while the expression of miR-940 was significantly decreased. (B) IHC assay showed that the expression of WDR5, CDK1, CDK2, CDK4, MMP2, and MMP9 were all increased significantly in mouse HCC tissue compared to those in normal tissue. The scale bar is 50 um. Data were expressed as mean ± SEM. **P<0.001.
Fig 3: CCDC144NL-AS1 promotes WDR5 to be recruited to the promoter region of MMPs and CDKs. ChIP assay showed that (A) the recruitment of WDR5 and (B) the H3K4me3 level in the promoter region of MMP2, MMP9, CDK1, CDK2, and CDK4 was regulated by CCDC144NL-AS1/miR-940 axis. Data were expressed as mean ± SEM. *P<0.05, **P<0.001.
Supplier Page from Abcam for Anti-MMP9 antibody [EPR22140-154] - BSA and Azide free